(Q51066066)

28 March 2018

title

Influence of previous use of inhaled corticoids on the development of pleural effusion in community-acquired pneumonia. (English)

1 reference

28 March 2018

0 references

8

1 reference

28 March 2018

Rosanel Amaro

Rosanel Amaro

5

0 references

Alejandra López-Giraldo

Alejandra López-Giraldo

2

0 references

Catia Cillóniz

Catia Cilloniz

4

0 references

Eva Polverino

Eva Polverino

6

0 references

author name string

Jacobo Sellares

1

1 reference

28 March 2018

Carmen Lucena

3

1 reference

28 March 2018

Miquel Ferrer

7

1 reference

28 March 2018

Josep Mensa

9

1 reference

28 March 2018

Antoni Torres

10

1 reference

28 March 2018

language of work or name

English

0 references

publication date

1 June 2013

1 reference

28 March 2018

American Journal of Respiratory and Critical Care Medicine

published in

1 reference

28 March 2018

volume

187

1 reference

28 March 2018

issue

11

1 reference

28 March 2018

page(s)

1241-1248

1 reference

28 March 2018

The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201209-1732OC

Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201209-1732OC

Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201209-1732OC

The natural history of community-acquired pneumonia in COPD patients: a population database analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201209-1732OC

Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201209-1732OC

Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201209-1732OC

Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201209-1732OC

Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201209-1732OC

Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201209-1732OC

A prediction rule to identify low-risk patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201209-1732OC

Medical and surgical treatment of parapneumonic effusions : an evidence-based guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201209-1732OC

Parapneumonic effusions and empyema

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201209-1732OC

Factors associated with prolonged hospital stay in community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201209-1732OC

Risk factors for complicated parapneumonic effusion and empyema on presentation to hospital with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201209-1732OC

Global initiative for asthma (GINA) and its objectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201209-1732OC

Inappropriate overuse of inhaled corticosteroids for COPD patients: impact on health costs and health status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201209-1732OC

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201209-1732OC

Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201209-1732OC

Defective macrophage phagocytosis of bacteria in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201209-1732OC

Macrophage activation in exacerbated COPD with and without community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201209-1732OC

Fluticasone propionate reduces bacterial airway epithelial invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201209-1732OC

Inhaled corticosteroids and risk of pneumonia: evidence for and against the proposed association

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201209-1732OC

Immunobiology of pleural inflammation: potential implications for pathogenesis, diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201209-1732OC

Inhaled drugs as risk factors for community-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201209-1732OC

Risks of pneumonia in patients with asthma taking inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201209-1732OC

Has the treatment of COPD changed in Spain? Results of a community multicenter study (VICE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201209-1732OC

The excessive use of inhaled corticosteroids in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201209-1732OC

Systematic review and meta-analysis on the association between outpatient statins use and infectious disease-related mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201209-1732OC

Is statin use associated with reduced mortality after pneumonia? A systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201209-1732OC

The role of statins in prevention and treatment of community acquired pneumonia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201209-1732OC

Anti-inflammatory effects of statins: clinical evidence and basic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201209-1732OC

[Confounding bias due to indication and severity in observational studies].

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201209-1732OC

Predictive factors, microbiology and outcome of patients with parapneumonic effusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201209-1732OC

10.1164/RCCM.201209-1732OC

21 January 2018

Identifiers

DOI

1 reference

28 March 2018

PubMed ID

23590264

1 reference

28 March 2018